^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ewing Sarcoma |
| Drug: | melphalan (Alkylating agent) + busulfan (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Summary of recommendations...Ewing Sarcoma...Recent studies recommend the use of BuMel for highly selected patients with poor response to induction ChT and/or tumour volume > 200 mL [I, B].
DOI:
10.1093/annonc/mdy310
